
Psoriasis is a chronic disease requiring long‐term therapy. Physician‐ and patient‐reported outcomes (PROs) were evaluated through week 252 in VOYAGE 1 and VOYAGE 2. A total of 1829 patients were randomized at baseline to receive guselkumab 100 mg every‐8‐weeks, placebo, or adalimumab; placebo patients crossed‐over to guselkumab at week 16. Adalimumab patients crossed‐over to guselkumab at week 52 in VOYAGE 1, and randomized‐withdrawal/retreatment occurred at weeks 28‐76 in VOYAGE 2; all patients then received open‐label guselkumab through week 252. Efficacy and HRQoL endpoints were analyzed through week 252. Safety was monitored through week 264...
Like
Save
Share